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Background
We have performed a blinded placebo-controlled study
immunizing antiretroviral (cART) treated chronically
HIV-1 infected patients with autologous Myeloid-
Derived Dendritic Cells (MD-DCs) pulsed with heat
inactivated autologous HIV-1.
Methods
36 patients with CD4+ >450 cells/mm3 were rando-
mized (2:1) to receive 3 immunizations every 2 weeks
with DC pulsed with autologous heat-inactivated HIV-1
(Cases, n=24) or with non-pulsed DC (Controls, n=12).
Changes in viral load (VL) as well as changes in CD4
cell counts have been evaluated. Additionally HIV speci-
fic responses were measured in PBMC samples from dif-
ferent time-points by LPR and by IFN-g-Elispot against
gag, nef and gp41 HIV overlapping peptide pools,
respectively.
Results
VL rebounded to detectable level in all the patients. At
week 12 and 24, a decrease of VL >= 1 log was observed
in 12/22 (55%) vs 1/11(9%) and in 7/20(35%) vs 0/10
(0%) in cases and controls, respectively (p=0.02, p=0.03).
CD4 drop to baseline value before any cART without
differences between groups. Although only transient
positive responses to HIV p24 were observed, the med-
ian change in LPR to HIV p24 at week 24 from baseline
was 0.96 vs -0.50 (p=0.02) in cases vs controls, respec-
tively. Baseline median values of the total sum of HIV
specific responses against HIV peptide pools were simi-
lar in both arms (2625 versus 2283 SFC/106 PBMC,
p=0.462). After vaccination, the median change of total
sum of SFC/106 PBMC at week 24 was 3567 vs 838
SFC/106 PBMC (p=0.0459) in cases and controls,
respectively. This difference was more evident when
analyzing responses against gag p17 and Nef peptide
pools (p=0.0288 and p=0.03615, respectively). No statis-
tically significant correlations between immune
responses and VL were found.
Conclusion
These results indicate that HIV-1 specific immune
responses elicited by therapeutic DC vaccines could sig-
nificantly change pVL set-point after cART interruption
in chronic HIV-1 infected patients.
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